# References — BPC-157 + TB-500 research blend

> The full reference list for Buy Wolverine. Peer-reviewed papers, reviews, and registry entries cited across the site's reading of the BPC-157 + TB-500 research literature.

Every numbered citation used across this site, in publication-date order with DOIs and PubMed or PubMed Central links to the underlying source.

## How to read this list

References are numbered in the order they first appear across the site, beginning on the home page and continuing through /research, /dosage, /faq, and /about. Each entry includes authors, title, journal, year, volume, DOI where available, and a direct link to the PubMed, PubMed Central, or publisher record.

The list covers 26 distinct primary and secondary sources. About a third are 2024 to 2025 reviews and primary studies; the remainder are foundational mechanism and clinical papers from 1991 through 2023. Where a citation refers to research on full-length thymosin beta-4 rather than the synthetic 7-residue TB-500 fragment, the per-page text flags that distinction inline.

## Full reference list

The full numbered list is rendered as a semantic ordered list below this section. Each entry can be cited from any page on the site via its numeric anchor.

## References

[1] Staresinic M, Sebecic B, Patrlj L, Jadrijevic S, Suknaic S, Perovic D, Aralica G, Zarkovic N, Borovic S, Srdjak M, Hajdarevic K, Kopljar M, Batelja L, Boban-Blagaic A, Turcic I, Anic T, Seiwerth S, Sikiric P. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. Journal of Orthopaedic Research. 2003;21(6):976-983. https://onlinelibrary.wiley.com/doi/10.1016/S0736-0266(03)00110-4
[2] Chang CH, Tsai WC, Hsu YH, Pang JHS. Pentadecapeptide BPC 157 Enhances the Growth Hormone Receptor Expression in Tendon Fibroblasts. Molecules. 2014;19(11):19066-19077. https://pmc.ncbi.nlm.nih.gov/articles/PMC6271067/
[3] Krivic A, Anic T, Seiwerth S, Huljev D, Sikiric P. Achilles detachment in rat and stable gastric pentadecapeptide BPC 157: promoted tendon-to-bone healing and opposed corticosteroid aggravation. Journal of Orthopaedic Research. 2006;24(5):982-989. https://pubmed.ncbi.nlm.nih.gov/16583442/
[4] Brcic L, Brcic I, Staresinic M, Novinscak T, Sikiric P, Seiwerth S. Modulatory effect of gastric pentadecapeptide BPC 157 on angiogenesis in muscle and tendon healing. Journal of Physiology and Pharmacology. 2009;60 Suppl 7:191-196. https://pubmed.ncbi.nlm.nih.gov/20388964/
[5] He L, Feng D, Guo H, et al. Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs. Frontiers in Pharmacology. 2022;13:1026182. https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2022.1026182/full
[6] McGuire FP, Martinez R, Lenz A, Skinner L, Cushman DM. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Current Reviews in Musculoskeletal Medicine. 2025;18(12):611-619. https://pmc.ncbi.nlm.nih.gov/articles/PMC12446177/
[7] Vasireddi N, Hahamyan H, Salata MJ, Karns M, Calcei JG, Voos JE, Apostolakos JM. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS Journal. 2025. https://journals.sagepub.com/doi/abs/10.1177/15563316251355551
[8] Bajramagic S, Sever M, Rasic F, Staresinic M, Skrtic A, Beketic Oreskovic L, et al. Stable Gastric Pentadecapeptide BPC 157 and Intestinal Anastomoses Therapy in Rats—A Review. Pharmaceuticals (Basel). 2024;17(8):1081. https://pmc.ncbi.nlm.nih.gov/articles/PMC11357423/
[9] Bock-Marquette I, Saxena A, White MD, Dimaio JM, Srivastava D. Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature. 2004;432(7016):466-472. https://pubmed.ncbi.nlm.nih.gov/15565145/
[10] Smart N, Risebro CA, Melville AAD, Moses K, Schwartz RJ, Chien KR, Riley PR. Thymosin β4 induces adult epicardial progenitor mobilization and neovascularization. Nature. 2007;445(7124):177-182. https://www.nature.com/articles/nature05383
[11] Sosne G, Qiu P, Kurpakus-Wheater M. Thymosin beta 4: A novel corneal wound healing and anti-inflammatory agent. Clinical Ophthalmology. 2007;1(3):201-207. https://pmc.ncbi.nlm.nih.gov/articles/PMC2701135/
[12] Guarnera G, DeRosa A, Camerini R. Thymosin beta-4 and venous ulcers: clinical remarks on a European prospective, randomized study on safety, tolerability, and enhancement on healing. Annals of the New York Academy of Sciences. 2007;1112:407-412. https://pubmed.ncbi.nlm.nih.gov/17495250/
[13] Sosne G, Dunn SP, Kim C. Thymosin β4 significantly improves signs and symptoms of severe dry eye in a phase 2 randomized trial. Cornea. 2015;34(5):491-496. https://pubmed.ncbi.nlm.nih.gov/25826322/
[14] Sosne G, Kim C, Kleinman HK. 0.1% RGN-259 (Thymosin β4) Ophthalmic Solution Promotes Healing and Improves Comfort in Neurotrophic Keratopathy Patients in a Randomized, Placebo-Controlled, Double-Masked Phase III Clinical Trial. International Journal of Molecular Sciences. 2023;24(1):554. https://pmc.ncbi.nlm.nih.gov/articles/PMC9820614/
[15] Wang T, Liu Q, Wang M, et al. A first-in-human, randomized, double-blind, single- and multiple-dose, phase I study of recombinant human thymosin β4 in healthy Chinese volunteers. Journal of Cellular and Molecular Medicine. 2021;25(18):8698-8708. https://pmc.ncbi.nlm.nih.gov/articles/PMC8419156/
[16] Kleinman HK, Sosne G. Thymosin β4 Promotes Dermal Healing. Vitamins and Hormones. 2016;102:251-275. https://pubmed.ncbi.nlm.nih.gov/27450738/
[17] Santra M, Chopp M, Zhang ZG, Lu M, Santra S, Nalani A, Santra S, Morris DC. Thymosin β4 mediates oligodendrocyte differentiation by upregulating p38 MAPK. Glia. 2012;60(12):1826-1838. https://pubmed.ncbi.nlm.nih.gov/23073962/
[18] Nguyen J, Verma S, Vuong VT, Queener H, Coulson-Thomas VJ, Gesteira TF. Engineered Tandem Thymosin Peptide Promotes Corneal Wound Healing. Investigative Ophthalmology & Visual Science. 2025;66(14):31. https://pmc.ncbi.nlm.nih.gov/articles/PMC12636994/
[19] Jozwiak M, Bauer M, Kamysz W, Kleczkowska P. Multifunctionality and Possible Medical Application of the BPC 157 Peptide—Literature and Patent Review. Pharmaceuticals (Basel). 2025;18(2):185. https://pmc.ncbi.nlm.nih.gov/articles/PMC11859134/
[20] Perovic D, Kolenc D, Bilic V, Somun N, Drmic D, Elabjer E, Buljat G, Seiwerth S, Sikiric P. Stable gastric pentadecapeptide BPC 157 can improve the healing course of spinal cord injury and lead to functional recovery in rats. Journal of Orthopaedic Surgery and Research. 2019;14(1):199. https://pubmed.ncbi.nlm.nih.gov/31266512/
[21] Matek D, Matek I, Staresinic E, Japjec M, Bojanic I, et al. Stable Gastric Pentadecapeptide BPC 157 as Therapy After Surgical Detachment of the Quadriceps Muscle from Its Attachments for Muscle-to-Bone Reattachment in Rats. Pharmaceutics. 2025;17(1):119. https://pmc.ncbi.nlm.nih.gov/articles/PMC11768438/
[22] Safer D, Elzinga M, Nachmias VT. Thymosin beta 4 binds actin in an extended conformation and contacts both the barbed and pointed ends. Journal of Biological Chemistry. 1991;266(7):4029-4032. https://pubmed.ncbi.nlm.nih.gov/1995650/
[23] Sosne G, Kleinman HK. Thymosin beta 4 and the eye: the journey from bench to bedside. Expert Opinion on Biological Therapy. 2018;18(sup1):99-104. https://www.tandfonline.com/doi/abs/10.1080/14712598.2018.1486818
[24] Goldstein AL, Hannappel E, Sosne G, Kleinman HK. Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opinion on Biological Therapy. 2012;12(1):37-51. https://pubmed.ncbi.nlm.nih.gov/22074294/
[25] World Anti-Doping Agency. The 2022 Prohibited List (and subsequent annual revisions). WADA. 2022-2025. https://www.wada-ama.org/en/prohibited-list
[26] Demirtas H, Ozer A, Yildirim AK, Dursun AD, Sezen SC, Arslan M. Protective Effects of BPC 157 on Liver, Kidney, and Lung Distant Organ Damage in Rats with Experimental Lower-Extremity Ischemia–Reperfusion Injury. Medicina (Kaunas). 2025;61(2):291. https://pmc.ncbi.nlm.nih.gov/articles/PMC11857380/
[27] Cha HJ, Jeong MJ, Kleinman HK. Role of thymosin beta4 in tumor metastasis and angiogenesis. Journal of the National Cancer Institute. 2003;95(22):1674-1680. https://pubmed.ncbi.nlm.nih.gov/14625258/
[28] Mendias CL, Awan TM. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports Medicine. 2026. https://pubmed.ncbi.nlm.nih.gov/41966639/
[29] Ho ENM, et al. Doping control analysis of TB-500, a synthetic version of an active region of thymosin beta4, in equine urine and plasma by liquid chromatography-mass spectrometry. Journal of Chromatography A. 2012;1265:57-66. https://pubmed.ncbi.nlm.nih.gov/23084823/
[30] Esposito S, et al. Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential. Drug Testing and Analysis. 2012;4(11):863-869. https://pubmed.ncbi.nlm.nih.gov/22962027/
[31] Ruff D, et al. A randomized, placebo-controlled, single and multiple dose study of intravenous thymosin beta4 in healthy volunteers. Annals of the New York Academy of Sciences. 2010;1194:223-229. https://pubmed.ncbi.nlm.nih.gov/20536472/
[32] Hsieh MJ, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. Journal of Molecular Medicine (Berlin). 2017;95(3):323-333. https://pubmed.ncbi.nlm.nih.gov/27847966/

---

A careful reading of the peer-reviewed record — not a clinic, not a vendor, not a dosing guide.